ANI Pharmaceuticals (NASDAQ:ANIP) Earns Outperform Rating from Analysts at Leerink Partners

Posted by Brenda Bartman on Sep 9th, 2026

Equities researchers at Leerink Partners began coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) in a research report issued on Wednesday, Briefing.com reports. The brokerage set an “outperform” rating and a $104.00 price target on the specialty pharmaceutical company’s stock. Leerink Partners’ price objective indicates a potential upside of 48.08% from the company’s previous close.

A number of other equities research analysts have also recently weighed in on ANIP. Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Canaccord Genuity Group lowered their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research note on Monday, August 10th. Guggenheim dropped their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $105.57.

View Our Latest Report on ANIP

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP opened at $70.23 on Wednesday. The firm’s 50 day moving average is $78.12 and its two-hundred day moving average is $78.34. The firm has a market capitalization of $1.61 billion, a P/E ratio of 15.14 and a beta of 0.45. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals has a 52 week low of $70.15 and a 52 week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last issued its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. The business had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The business’s revenue for the quarter was up 25.8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Analysts anticipate that ANI Pharmaceuticals will post 7.83 earnings per share for the current year.

Insider Buying and Selling

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 3,313 shares of the business’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $86.00, for a total transaction of $284,918.00. Following the sale, the chief financial officer owned 177,543 shares in the company, valued at approximately $15,268,698. The trade was a 1.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Meredith Cook sold 500 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $75.48, for a total transaction of $37,740.00. Following the sale, the vice president directly owned 74,424 shares of the company’s stock, valued at $5,617,523.52. This represents a 0.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 21,925 shares of company stock worth $1,728,385. Company insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Penn Capital Management Company LLC increased its holdings in shares of ANI Pharmaceuticals by 2,058.9% in the 4th quarter. Penn Capital Management Company LLC now owns 137,394 shares of the specialty pharmaceutical company’s stock valued at $10,858,000 after purchasing an additional 131,030 shares during the period. Vanguard Group Inc. boosted its holdings in shares of ANI Pharmaceuticals by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock worth $103,022,000 after purchasing an additional 27,598 shares during the period. CenterBook Partners LP acquired a new stake in shares of ANI Pharmaceuticals during the fourth quarter worth approximately $1,518,000. Jupiter Topco LLC purchased a new position in ANI Pharmaceuticals during the second quarter valued at approximately $6,597,000. Finally, NFJ Investment Group LLC purchased a new position in ANI Pharmaceuticals during the second quarter valued at approximately $2,766,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

(Get Free Report)

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.